Cargando…
Targeting KRAS(G12C) in colorectal cancer: the beginning of a new era
RAS mutation is considered one of the most relevant oncogenic drivers in human cancers. Unfortunately, for more than three decades, RAS has been considered an undruggable target. Recently, the discovery of selective and potent KRAS(G12C) inhibitors represented a light at the end of the tunnel. Indee...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800313/ https://www.ncbi.nlm.nih.gov/pubmed/36549128 http://dx.doi.org/10.1016/j.esmoop.2022.100745 |